Residual Symptoms and Recurrence During Maintenance Treatment of Late-life Depression

Overview

Journal J Affect Disord

Date 2007 Feb 27

PMID 17321595

Citations 55

Authors

Alexandre Y Dombrovski

Benoit H Mulsant

Patricia R Houck

Sati Mazumdar

Eric J Lenze

Carmen Andreescu

Jill M Cyranowski

Charles F Reynolds 3rd

Affiliations

Soon will be listed here.

Abstract

Background: Many older patients who recover from an episode of major depression continue to suffer from depressed mood, anxiety, and sleep problems. Our study assesses the impact of these residual symptoms on the risk of recurrence during maintenance treatment of late-life depression.

Method: We analyzed data from a randomized clinical trial of maintenance treatment in patients with unipolar depression aged > or =70, 116 of whom remitted and remained stable during open pharmacotherapy and interpersonal psychotherapy (IPT) and were randomized to clinical management/pharmacotherapy; clinical management/placebo; monthly maintenance IPT/ pharmacotherapy; or monthly maintenance IPT/placebo. We assessed the impact of overall residual symptoms (based on the Hamilton Depression Rating Scale (HAM-D) total score) and of specific residual symptom clusters - mood symptoms (depressed mood, guilt, suicidality, energy/interests), sleep disturbance (early, middle, late insomnia), and anxiety (agitation, psychic and somatic anxiety, hypochondriasis) measured at randomization. Sleep disturbance was also assessed with the Pittsburgh Sleep Quality Index (PSQI). We used Cox proportional hazards regression models controlling for assignment to antidepressant medication versus placebo to identify predictors of recurrence.

Results: Residual anxiety and residual sleep disturbance (as measured by the PSQI but not the HAM-D) independently predicted early recurrence.

Limitations: Use of HAM-D clusters to define residual symptoms; analysis limited to completers of acute and continuation treatment.

Conclusions: In patients with late-life depression who have remitted with pharmacotherapy and psychotherapy, the deleterious effect of residual symptoms is due to persisting anxiety and, possibly, residual sleep disturbance.

Citing Articles

Unveiling the interoception impairment in various major depressive disorder stages.

Zhou H, Liu J, Wu Y, Huang Z, Wang W, Ma Y CNS Neurosci Ther. 2024; 30(8):e14923.

PMID: 39154365 PMC: 11330652. DOI: 10.1111/cns.14923.

Cortical signatures of sleep are altered following effective deep brain stimulation for depression.

van Rheede J, Alagapan S, Denison T, Riva-Posse P, Rozell C, Mayberg H Transl Psychiatry. 2024; 14(1):103.

PMID: 38378677 PMC: 10879134. DOI: 10.1038/s41398-024-02816-z.

Therapeutic Potential of Myricetin in the Treatment of Neurological, Neuropsychiatric, and Neurodegenerative Disorders.

Sethiya N, Ghiloria N, Srivastav A, Bisht D, Chaudhary S, Walia V CNS Neurol Disord Drug Targets. 2023; 23(7):865-882.

PMID: 37461364 DOI: 10.2174/1871527322666230718105358.

Exploratory Validation of Sleep-Tracking Devices in Patients with Psychiatric Disorders.

Ogasawara M, Takeshima M, Kosaka S, Imanishi A, Itoh Y, Fujiwara D Nat Sci Sleep. 2023; 15:301-312.

PMID: 37123093 PMC: 10143764. DOI: 10.2147/NSS.S400944.

Does insomnia treatment prevent depression?.

Boland E, Goldschmied J, Gehrman P Sleep. 2023; 46(6).

PMID: 37029781 PMC: 10262035. DOI: 10.1093/sleep/zsad104.

References

Hertzberg M, Butterfield M, Feldman M, Beckham J, Sutherland S, Connor K . A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry. 1999; 45(9):1226-9. DOI: 10.1016/s0006-3223(99)00011-6. View

Pande A, Davidson J, Jefferson J, Janney C, Katzelnick D, Weisler R . Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol. 1999; 19(4):341-8. DOI: 10.1097/00004714-199908000-00010. View

Frank E, Shear M, Rucci P, Cyranowski J, Endicott J, Fagiolini A . Influence of panic-agoraphobic spectrum symptoms on treatment response in patients with recurrent major depression. Am J Psychiatry. 2000; 157(7):1101-7. DOI: 10.1176/appi.ajp.157.7.1101. View

Pande A, Pollack M, Crockatt J, Greiner M, Chouinard G, Lydiard R . Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol. 2000; 20(4):467-71. DOI: 10.1097/00004714-200008000-00011. View

Ghali W, Quan H, Brant R, van Melle G, Norris C, Faris P . Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA. 2001; 286(12):1494-7. DOI: 10.1001/jama.286.12.1494. View

Lenze E, Mulsant B, Shear M, Alexopoulos G, Frank E, Reynolds 3rd C . Comorbidity of depression and anxiety disorders in later life. Depress Anxiety. 2001; 14(2):86-93. DOI: 10.1002/da.1050. View

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

Wetherell J, Gatz M, Craske M . Treatment of generalized anxiety disorder in older adults. J Consult Clin Psychol. 2003; 71(1):31-40. DOI: 10.1037//0022-006x.71.1.31. View

Manber R, Rush A, Thase M, Amow B, Klein D, Trivedi M . The effects of psychotherapy, nefazodone, and their combination on subjective assessment of disturbed sleep in chronic depression. Sleep. 2003; 26(2):130-6. DOI: 10.1093/sleep/26.2.130. View

10.

Kanai T, Takeuchi H, Furukawa T, Yoshimura R, Imaizumi T, Kitamura T . Time to recurrence after recovery from major depressive episodes and its predictors. Psychol Med. 2003; 33(5):839-45. DOI: 10.1017/s0033291703007827. View

11.

Hamilton M . A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56-62. PMC: 495331. DOI: 10.1136/jnnp.23.1.56. View

12.

Boulenger J . Residual symptoms of depression: clinical and theoretical implications. Eur Psychiatry. 2004; 19(4):209-13. DOI: 10.1016/j.eurpsy.2004.04.001. View

13.

Karp J, Buysse D, Houck P, Cherry C, Kupfer D, Frank E . Relationship of variability in residual symptoms with recurrence of major depressive disorder during maintenance treatment. Am J Psychiatry. 2004; 161(10):1877-84. DOI: 10.1176/ajp.161.10.1877. View

14.

Bagby R, Ryder A, Schuller D, Marshall M . The Hamilton Depression Rating Scale: has the gold standard become a lead weight?. Am J Psychiatry. 2004; 161(12):2163-77. DOI: 10.1176/appi.ajp.161.12.2163. View

15.

Whyte E, Basinski J, Farhi P, Dew M, Begley A, Mulsant B . Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors. J Clin Psychiatry. 2005; 65(12):1634-41. DOI: 10.4088/jcp.v65n1208. View

16.

Wetherell J, Sorrell J, Thorp S, Patterson T . Psychological interventions for late-life anxiety: a review and early lessons from the CALM study. J Geriatr Psychiatry Neurol. 2005; 18(2):72-82. DOI: 10.1177/0891988705276058. View

17.

Cyranowski J, Frank E, Shear M, Swartz H, Fagiolini A, Scott J . Interpersonal psychotherapy for depression with panic spectrum symptoms: a pilot study. Depress Anxiety. 2005; 21(3):140-2. DOI: 10.1002/da.20069. View

18.

Alexopoulos G, Katz I, Reynolds 3rd C, Carpenter D, Docherty J, ROSS R . Pharmacotherapy of depression in older patients: a summary of the expert consensus guidelines. J Psychiatr Pract. 2005; 7(6):361-76. DOI: 10.1097/00131746-200111000-00003. View

19.

Rickels K, Pollack M, Feltner D, Lydiard R, Zimbroff D, Bielski R . Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005; 62(9):1022-30. DOI: 10.1001/archpsyc.62.9.1022. View

20.

Morse J, Pilkonis P, Houck P, Frank E, Reynolds 3rd C . Impact of cluster C personality disorders on outcomes of acute and maintenance treatment in late-life depression. Am J Geriatr Psychiatry. 2005; 13(9):808-14. DOI: 10.1176/appi.ajgp.13.9.808. View